XTRA:MRKPharmaceuticals
Assessing Merck KGaA (XTRA:MRK) Valuation After Fresh Value Calls And New Genetix Gene Therapy Agreement
Merck KGaA (XTRA:MRK) has been in focus after recent value oriented analyst coverage and the announcement of a five year agreement with Genetix Biotherapeutics, covering testing services for FDA approved gene therapies.
See our latest analysis for Merck KGaA.
Recent news, including the Genetix agreement and first quarter earnings, has coincided with a 6.50% 7 day share price return to €120.35. However, the 90 day share price return declined 6.38% and the 3 year total shareholder return is...